The lowest practical MOQ for a private label bifida ferment lysate serum is typically 100–250 units, and this tier is served almost exclusively by boutique contract manufacturers in South Korea, the United States (California, New Jersey, and Texas hubs), and a smaller cluster in the UK. At 100 units you are essentially paying a premium for flexibility: expect unit costs in the $12–$18 range for a 30 mL glass dropper format before duty and freight. That high per-unit cost reflects fixed batch overheads—equipment setup, quality-control testing, label application—spread across very few units.
MOQ is not a single fixed number across the industry; it moves based on several real variables. First, formula type matters enormously. A manufacturer's existing stock or white-label formula has already been stability-tested and safety-assessed, so they can run it at 100–250 units without absorbing development costs. A fully bespoke formula—where you specify a precise bifida ferment lysate percentage, a custom peptide pairing, and a specific texture profile—requires formulation labor, raw-material qualification, and 8–12 weeks of stability testing. That investment pushes the MOQ up to 500–1,000 units because the factory needs enough units to amortize development.
Second, packaging selection drives MOQ independently. Airless pump bottles and glass dropper bottles with custom decoration (hot-stamp, frosted glass, silk screen) typically carry their own component MOQ of 500–1,000 pieces from the packaging supplier. If your component MOQ is 500, your serum MOQ is effectively at least 500 regardless of what the fill house says. Opting for stock packaging—a plain amber glass dropper available off-the-shelf—removes that constraint and can keep your serum MOQ as low as 100.
Third, geography affects MOQ. Korean contract manufacturers (OEM/ODM houses in the Gyeonggi region) are the global leaders in ferment-active serums but many start at 500–1,000 units for international buyers because of shipping container economics and export documentation overhead. Domestic US manufacturers often accept 100–300 units but their bifida ferment lysate ingredient sourcing may add cost compared to Korean facilities that have preferred supplier relationships with domestic fermentation houses.
The most common mistake first-time founders make is negotiating MOQ without negotiating the payment schedule simultaneously. A manufacturer willing to do 150 units but requiring 100% payment upfront is a very different risk profile from one that accepts 50% on formula approval and 50% on delivery. AJ Cosmo Labs connects founders with vetted manufacturers and allows milestone-based escrowed payments, which reduces upfront risk when working at these small volumes.
Read the full guide on Private Label Bifida Ferment Lysate Serum Manufacturer Low MOQ →